Related Experiment Video
Updated: Jul 11, 2026

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
Published on: October 2, 2018
[Syndrome of persistent low levels of human chorionic gonadotrophin (hCG)]
M Zavadil1, J Feyereisl, P Safár
1Centrum pro trofoblastickou nemoc v CR, Praha. zavadilctn@updm.cz
Insights
Persistent low levels of hCG (human chorionic gonadotropin) can be misdiagnosed, leading to unnecessary treatments. Proper classification and monitoring are crucial for managing this condition, which may indicate persistent trophoblastic invasion.
Area of Science:
- Gynecology and Obstetrics
- Reproductive Endocrinology
- Oncology
Context:
- Persistent low levels of human chorionic gonadotropin (hCG) present a diagnostic challenge in gynecological and obstetrical settings.
- This syndrome can mimic or be confused with trophoblastic disease, leading to inappropriate medical interventions.
Purpose:
- To analyze the etiology, classification, diagnosis, and management of persistent low levels of hCG (PLL).
- To differentiate between various causes of PLL, including false positives, hypophysial origin, and trophoblastic origins.
- To highlight the risks of misdiagnosis and the contraindication of chemotherapy and surgery for PLL.
Summary:
- Persistent low levels of hCG (PLL) were analyzed in 29 women, classifying them into false positive, hypophysial, quiescent trophoblastic disease, and undetermined types.
- The study found that PLL is often misdiagnosed as trophoblastic disease, resulting in 40-80% of patients undergoing unnecessary chemotherapy and operations.
- PLL-Q and PLL-U, assumed to be of trophoblastic origin, require continuous monitoring and may indicate persistent trophoblastic invasion with a 7-25% risk of malignant transformation.
Impact:
- Clarifies the classification and diagnosis of persistent low hCG levels, reducing misdiagnosis rates.
- Emphasizes the contraindication of chemotherapy and surgery for PLL, preventing unnecessary patient harm.
- Recommends specialized monitoring for specific PLL subtypes, potentially improving outcomes and identifying malignant transformation risks.
Objective:
To analyze the syndrome of persistent low levels of hCG in terms of its etiology, classification, diagnosis, and management.
Design:
Retrospective analysis.
Setting:
Center for Trophoblastic Disease in Czech Republic, Institute for Care of Mother and Child, Prague, Institute of Postgraduate medical education, IPVZ, Prague
Methods:
An analysis of the syndrome of persistent low levels of hCG recorded in CTN in 29 women in the years 1979-2005 by the immunoluminesence method which can quantitatively assess variable levels of hCG in blood and urine. A comparison was made of our findings with results of a similar studies having been done in England and USA.
Results:
Persistent low levels of hCG (PLL) can be differentiated according to cause. 1. PLL-F False positive, also known as Phantom hCG, often caused by heterogenous antibodies. 2. PLL-H Of hypophysial origin, mainly in perimenopause and menopause. 3. PLL-Q Quiescent with trophoblastic disease in history, of trophoblastic origin. 4. PLL-U Undetermined, in history without trophoblastic disease, but in the past with physiological or pathological pregnancy. Assuming also to be of trophoblastic origin. All types of PLL lead in practice to the wrong diagnosis of trophoblastic disease and to a high percentage (40-80%) of needless chemotherapy and operations. In no case of PLL did chemotherapy or operations have an effect on PLL and thus are contraindicated. PLL-Q and PLL-U require continuous clinical and laboratory monitoring and repeated examinations with sophisticated visualization methods. The percentage of developing malignant trophoblastic tumors after PLL-Q and PLL-U is unclear. Extreme incidence was established in 7-25%. PLL-Q and PLL-U are considered as a marker of persistent trophoblastic invasion. Its detection by visualization methods in any organ localization before it turns into a limited solid tumor is excluded by it microscopic dissociative structure.
Conclusion:
The syndrome of persistent low levels of hCG (PLL) lately affects all gynecological and obstetrical workplaces. According to cause it can be divided into: 1. PLL false positive, 2. PLL of hypophysial origin, 3.PLL quiescent with trophoblastic disease in the history, 4. PLL undetermined, in history without trophoblastic disease. In the last two items mentioned above we assume to be of trophoblastic origin. Their morphological base is persistent trophoblastic invasion. The syndrome of PLL often leads to the wrong diagnosis of trophoblastic disease and to needless chemotherapy and operations. In this work was described the diagnosis of PLL, its classification, cause, and management. The percentage of PLL turned into malignant trophoblastic disease is unknown and ranges from 7-25% and requires monitoring in an accredited, national center for trophoblastic disease.
More Related Videos
Related Concept Videos
Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Ovarian Cycle
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Hypothyroidism II: Pathophysiology
Cushing Syndrome II: Pathophysiology

